Cedric Folens

Efficacy of the Kinase Inhibitor SU11248 against Gastrointestinal Stromal Tumor Mutants Refractory to Imatinib Mesylate

P. Marynen, R. Sciot, M. Debiec‐Rychter, 2006, Clinical Cancer Research.

Kinase activation and transformation by NUP214-ABL1 is dependent on the context of the nuclear pore.

P. Marynen, M. Fornerod, D. Gilliland, 2008, Molecular cell.

In vitro validation of γ-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia

P. Marynen, M. Odero, L. van Neste, 2008, Haematologica.

Activation of FIP1L1-PDGFRα requires disruption of the juxtamembrane domain of PDGFRα and is FIP1L1-independent

P. Marynen, D. Gilliland, J. Cools, 2006 .

Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutant

P. Marynen, J. Cools, N. Mentens, 2006 .

Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.

P. Marynen, J. Cools, N. Mentens, 2006, Blood.

A new NDE1/PDGFRB fusion transcript underlying chronic myelomonocytic leukaemia in Noonan Syndrome

P. Marynen, C. Mecucci, M. Martelli, 2007, Leukemia.